BCL2 and Thrombocytopenia: This translates into increased potency and efficacy in pre-clinical models of lymphoid malignancies that are dependent on BCL-2 for survival.20 Importantly, its lack of affinity for BCL-XL circumvents thrombocytopenia, a dose-limiting toxicity associated with navitoclax.20 Subsequently, objective responses have been obtained in clinical trials of venetoclax in chronic lymphocytic leukemia43 and NHL44 patients.